April 1, 2021

Cindy Findley
Deputy Secretary, Health Promotion and Disease Prevention
Pennsylvania Department of Health
625 Forster Street, 8th Floor
West Harrisburg, PA 17120

Dear Deputy Secretary Findley:

On behalf of the approximately 1,500 people living with cystic fibrosis in Pennsylvania, we write today to urge the state to ensure all people with high-risk medical conditions—including cystic fibrosis—are prioritized for early access to COVID-19 vaccines. The Centers for Disease Control and Prevention (CDC) recently updated its list of medical conditions that can increase the risk of worse outcomes from COVID-19 infection and includes CF.¹ We urge Pennsylvania to immediately revise its vaccine prioritization plan to reflect this update.

**Background on Cystic Fibrosis and COVID-19**

The Cystic Fibrosis Foundation is a national organization actively engaged in the research and development of new therapies for cystic fibrosis—a rare, life-threatening genetic disease that affects more than 30,000 people in the United States. The buildup of thick, sticky mucus in the lungs characteristic of the disease makes people with CF particularly prone to chronic respiratory infections. These chronic infections are punctuated by pulmonary exacerbations, events that are a risk factor for an irreversible decline of lung function and associated with morbidity and mortality. A significant proportion of pulmonary exacerbations are triggered by respiratory viral infections. Continued progression of the disease can result in advanced lung disease so severe that lung transplantation may be the only life extending option.

The absent or malfunctioning protein that causes CF is also associated with a wide range of disease manifestations beyond the lungs, including pancreatic insufficiency that can lead to malnutrition, gastrointestinal issues, biliary cirrhosis, and diabetes mellitus.

While we have seen incredible progress in recent decades for those living with cystic fibrosis, COVID-19 represents a serious threat for this population. The strongest evidence to date on the threat COVID-19 poses to those with CF comes from a global analysis of 181 COVID-19 cases among people with CF.² From that analysis, it appears CF patients with advanced lung disease, those that are post-lung transplantation, and those with diabetes mellitus may be at risk of severe outcomes including death.

---

Due to the known risks posed by viral infections, the multi-system manifestations of the disease described above, and evidence demonstrating the impacts of COVID-19 infection for those living with CF, the CDC has listed CF as a condition that can put individuals at increased risk for worse outcomes.3

**Individuals with Cystic Fibrosis Must Be Prioritized for Access to COVID-19 Vaccines**

We are concerned that Pennsylvania’s plan inappropriately excludes people with CF from priority COVID-19 vaccine access. We urge the state to revise its vaccine prioritization plan in accordance with recent updates to the CDC’s list of high-risk medical conditions, *People with Certain Medical Conditions*,4 so that all individuals with high-risk conditions receive prioritized vaccine access.

On March 29th, the CDC revised the list of high-risk conditions by removing the categories designating conditions as “known to increase risk” or “might increase risk” of severe illness. As noted by the CDC, all conditions contained on the revised list—including CF—meet criteria indicating higher risk for worse outcomes from COVID-19 based on available evidence.

Pennsylvania should immediately revise the state’s vaccine allocation plan to align with the CDC’s revised list of high-risk medical conditions. It is critical that the state act quickly to ensure that individuals with CF are able to access COVID-19 vaccines alongside others with high-risk conditions.

********

Once again, we thank you for your attention and consideration of people with CF as you tackle these difficult issues. It is critical that vaccine prioritization reflects the latest evidence on risk and supports access for vulnerable populations like those living with CF and other high-risk conditions. We look forward to working with you as the state continues to update allocation recommendations for COVID-19 vaccines.

Sincerely,

**Mary B. Dwight**  
Chief Policy and Advocacy Officer  
Senior Vice President of Policy and Advocacy  
Cystic Fibrosis Foundation

**Denis Hadjiliadis, MD**  
Director, Adult CF Care Center  
University of Pennsylvania  
Philadelphia, PA

**Gavin Graff, MD**  
Director, Pediatric CF Care Center  
Hershey Medical Center Pennsylvania State University  
Hershey, PA

**Robert Miller, MD**  
Director, Affiliate CF Care Center  
Lehigh Valley Children’s Hospital CFC  
Allentown, PA

---

Joseph Pilewski, MD  
Director, Adult CF Care Center  
University of Pittsburgh Medical Center  
Pittsburgh, PA

Catherine Shoff, DO  
Director, Adult CF Care Center  
Geisinger Medical Center  
Danville, PA

Jonathan Spahr, MD  
Director, Pediatric CF Care Center  
Geisinger Medical Center  
Danville, PA

Michael Stephen, MD  
Director, Adult CF Care Center  
Jefferson University Hospital  
Philadelphia, PA

Laurie Varlotta, MD  
Director, Pediatric CF Care Center  
St. Christopher's Hospital for Children  
Philadelphia, PA

Daniel Weiner, MD  
Director, Pediatric CF Care Center  
UPMC Children's Hospital of Pittsburgh  
Pittsburgh, PA

Lisa Young, MD  
Director, Pediatric CF Care Center  
Children's Hospital of Philadelphia  
Philadelphia, PA